Press Release: Santhera: Full Year Trading Update -2-

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE(R) (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), in China by the National Medical Products Administration (NMPA) and Hong Kong by the Department of Health (DoH). Santhera has out-licensed rights to AGAMREE for North America to Catalyst Pharmaceuticals and for China and certain countries in Southeast Asia to Sperogenix Therapeutics. For further information, please visit www.santhera.com.

AGAMREE(R) is a trademark of Santhera Pharmaceuticals.

For further information please contact:

public-relations@santhera.com https://www.globenewswire.com/Tracker?data=tPmzTqPENqN1i-SWwbNDpGPk-8Hmw-NwElDy1n2gqpqe_v5cSpMrIxbYIlG49l_d9uyGBJDbgceAzvCi_8BohvAT6NwRuK-QE5K0ZvGBOfEKaSZHoWb3kAU_T67sMB3m or

Catherine Isted, Chief Financial Officer

Catherine.Isted@Sanathera.com https://www.globenewswire.com/Tracker?data=nt0hKs-ZqOh39CYu-P-gkEIGfLwtO5I4W3Q7TEiTe4TnP3ndmoQ_uosI9diaBnvxos3gYvmc6ebEU6UvPLmGttLXfcjnhqcZkvSiH42yaDb7Frye71rqJgT2QLuM__3U

Disclaimer / Forward-looking

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

Attachment

-- 250304 Santhera Trading Update v4_FINAL

https://ml-eu.globenewswire.com/Resource/Download/edd71b0e-3592-42be-aa61-f6eae58476a0

(END) Dow Jones Newswires

March 04, 2025 01:00 ET (06:00 GMT)